Matinas BioPharma Holdings, Inc. Income Statement
MTNB|10 years of annual SEC 10-K data (FY2015-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 10 fiscal years. All figures from audited SEC 10-K filings.
Revenue has grown at a 41.8% compound annual rate over the past 8 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $3.2M | $33.0K | $33.0K | $158.3K | $119.8K | $149.7K | $194.5K | $0 | $194.5K |
| SG&A Expense | $8.7M | $11.1M | $10.2M | $10.2M | $10.0M | $8.0M | $7.6M | $4.8M | $4.3M | $4.8M |
| R&D Expense | $11.4M | $16.7M | $14.6M | $14.6M | $14.4M | $6.8M | $9.0M | $5.3M | $3.9M | $5.3M |
| Operating Income | -$24.6M | -$24.6M | -$24.7M | -$24.7M | -$24.2M | -$14.6M | -$16.5M | -$9.9M | -$8.3M | -$9.9M |
| Income Tax | -$80.0K | - | - | - | - | $400.0K | -$357.0K | -$357.0K | - | - |
| Net Income | -$24.3M | -$21.0M | -$23.3M | -$23.3M | -$22.4M | -$14.1M | -$15.5M | -$9.1M | -$7.6M | -$9.1M |
| EPS (Basic) | -$5.28 | -$0.10 | -$0.11 | - | - | - | - | - | - | - |
| EPS (Diluted) | -$5.28 | -$0.10 | - | -$0.12 | -$0.13 | -$0.15 | -$0.36 | -$0.18 | -$0.18 | -$0.32 |
| Shares Outstanding | 4.3M | 217.3M | 216.3M | 200.1M | 163.2M | 113.3M | 93.4M | 58.2M | 57.2M | 32.3M |
| Operating Margin | - | -771.3% | -74954.5% | -74954.5% | -15288.4% | -12230.9% | -11024.6% | -5096.0% | - | -5096.0% |
| Profit Margin | - | -658.6% | -70554.5% | -70554.5% | -14177.0% | -11760.4% | -10345.9% | -4697.0% | - | -4697.0% |